HUP9900037A2 - Apoptózis inhibitorként használható RAR-gamma-antagonista vagy RAR-alfa-agonista ligandum alkalmazása apoptózis inhibitorként használható gyógyszerkészítmény előállítására - Google Patents

Apoptózis inhibitorként használható RAR-gamma-antagonista vagy RAR-alfa-agonista ligandum alkalmazása apoptózis inhibitorként használható gyógyszerkészítmény előállítására

Info

Publication number
HUP9900037A2
HUP9900037A2 HU9900037A HUP9900037A HUP9900037A2 HU P9900037 A2 HUP9900037 A2 HU P9900037A2 HU 9900037 A HU9900037 A HU 9900037A HU P9900037 A HUP9900037 A HU P9900037A HU P9900037 A2 HUP9900037 A2 HU P9900037A2
Authority
HU
Hungary
Prior art keywords
rar
alfa
pharmaceutical compositions
prepare pharmaceutical
reducing apoptosis
Prior art date
Application number
HU9900037A
Other languages
English (en)
Inventor
László Fésüs
Uwe Reichert
Zsuzsa Szondy
Original Assignee
Centre International De Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International De Recherches Dermatologiques Galderma filed Critical Centre International De Recherches Dermatologiques Galderma
Publication of HUP9900037A2 publication Critical patent/HUP9900037A2/hu
Publication of HUP9900037A3 publication Critical patent/HUP9900037A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)

Abstract

A találmány tárgya legalább egy ligandűm, amely lehet RAR-a-típűsúreceptőr specifikűs agőnista ligandűma, vagy RAR-g-típűsúreceptőrspecifikűs antagőnista ligandűma, alkalmazása az apőptózisarányának legalább egy sejtpőpűlációban való csökkentésére alkalmas,amely legalább egy sejtpőpűlációban túlzőtt apőptózissal kapcsőlatős. ŕ
HU9900037A 1995-10-11 1996-10-08 Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis HUP9900037A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9511946A FR2739777B1 (fr) 1995-10-11 1995-10-11 Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose

Publications (2)

Publication Number Publication Date
HUP9900037A2 true HUP9900037A2 (hu) 1999-04-28
HUP9900037A3 HUP9900037A3 (en) 1999-11-29

Family

ID=9483437

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900037A HUP9900037A3 (en) 1995-10-11 1996-10-08 Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis

Country Status (21)

Country Link
US (1) US6063797A (hu)
EP (1) EP0854711B1 (hu)
JP (1) JP3135267B2 (hu)
KR (1) KR100300214B1 (hu)
CN (1) CN1104896C (hu)
AT (1) ATE212226T1 (hu)
AU (1) AU695311B2 (hu)
BR (1) BR9611035A (hu)
CA (1) CA2231558C (hu)
DE (1) DE69618802T2 (hu)
DK (1) DK0854711T3 (hu)
ES (1) ES2172680T3 (hu)
FR (1) FR2739777B1 (hu)
HU (1) HUP9900037A3 (hu)
NO (1) NO981652L (hu)
NZ (1) NZ319647A (hu)
PL (1) PL186821B1 (hu)
PT (1) PT854711E (hu)
RU (1) RU2191008C2 (hu)
TR (1) TR199800644T2 (hu)
WO (1) WO1997013506A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
CA2344653A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU2001290816A1 (en) * 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
BRPI0519111A2 (pt) * 2004-12-17 2008-12-23 Wyeth Corp mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
MX361414B (es) * 2010-09-01 2018-12-05 Univ Jefferson Composición y método para reparación y regeneración muscular.
CN104204192A (zh) 2012-02-13 2014-12-10 加米达细胞有限公司 间充质干细胞调理的基质及其产生和使用方法
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9861640B2 (en) 2013-06-10 2018-01-09 Kemphys Ltd. Medicament for treatment of Alzheimer's disease
JP2018512396A (ja) * 2015-03-09 2018-05-17 キングス・カレッジ・ロンドン Ｔｈ１応答を増強するためのｒａｒアルファアゴニストを用いた併用療法
EP3967305A1 (en) 2015-03-31 2022-03-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
EP3440046A1 (en) * 2016-04-07 2019-02-13 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2017177167A1 (en) 2016-04-08 2017-10-12 Syros Pharmaceuticals, Inc. Rara agonists for the treatment of aml and mds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
AU7221096A (en) 1997-04-30
RU2191008C2 (ru) 2002-10-20
EP0854711B1 (fr) 2002-01-23
EP0854711A1 (fr) 1998-07-29
AU695311B2 (en) 1998-08-13
KR100300214B1 (ko) 2001-11-22
HUP9900037A3 (en) 1999-11-29
WO1997013506A1 (fr) 1997-04-17
FR2739777B1 (fr) 1997-11-14
NO981652L (no) 1998-06-10
PT854711E (pt) 2002-05-31
FR2739777A1 (fr) 1997-04-18
PL186821B1 (pl) 2004-03-31
CN1104896C (zh) 2003-04-09
CA2231558C (fr) 2003-05-27
ATE212226T1 (de) 2002-02-15
ES2172680T3 (es) 2002-10-01
JPH11500448A (ja) 1999-01-12
DE69618802T2 (de) 2002-11-14
KR19990064204A (ko) 1999-07-26
BR9611035A (pt) 1999-07-06
DK0854711T3 (da) 2002-03-25
TR199800644T2 (xx) 1998-07-21
PL326162A1 (en) 1998-08-31
US6063797A (en) 2000-05-16
CN1203529A (zh) 1998-12-30
JP3135267B2 (ja) 2001-02-13
NO981652D0 (no) 1998-04-08
DE69618802D1 (de) 2002-03-14
CA2231558A1 (fr) 1997-04-17
NZ319647A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
HUP9900037A2 (hu) Apoptózis inhibitorként használható RAR-gamma-antagonista vagy RAR-alfa-agonista ligandum alkalmazása apoptózis inhibitorként használható gyógyszerkészítmény előállítására
IT1206096B (it) Impianto di conferenza digitale distribuito.
NO981592L (no) Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten
DE3774209D1 (de) Stabilisierte polyvinylchloridzusammensetzung.
DE69005732D1 (de) Baggerzahn.
PT817847E (pt) Receptor de il-17
NL192201B (nl) Farmacologisch actieve fenylaminoalkylcyclobutaanverbindingen en prepa- raten die deze verbindingen bevatten.
DE69422371D1 (de) Baggerzahn zur adapter schnittstelle
DE58903843D1 (de) Brausetablette.
DE3852988D1 (de) Propylen-Ethylen-Blockcopolymer Zusammensetzung.
EP0621338A3 (en) The interleukin-2 response blocking immunosuppressor.
NO934066D0 (no) Middel til hindring av polymeravleiring
DE69300957D1 (de) Kathodischer Korrosionsschutz.
TR25037A (tr) Sivi ter kesici terkipleri.
NO900564L (no) Overflateaktivt middel.
DE58901402D1 (de) Metallische flachdichtung.
FR2694188B3 (fr) Chaise pour bloc dentaire.
DE68912159D1 (de) Dioxoquinazolinderivat enthaltendes Antihypertensivum.
IT1150211B (it) 1,2,3,4-tetraidronaftaleni sostituiti con amminoalchili adazione farmaceutica
NL191226C (nl) Dynamische hoofdtelefoon.
FI892260A0 (fi) Komposition med hoeg fastaemneshalt foer bestrykning av papper.
ES1016779Y (es) Calendario de sobremesa.
FR2661803B1 (fr) Combinaison de protection pour salle propre.
KR930002785U (ko) 조경을 겸한 비탈면 보호블록
KR950003118U (ko) 경기장의 라인 표시기